New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
06:11 EDTNOK, UBS, GSK, SI, FLOOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Switzerland and the U.K. announced punitive measures against UBS (UBS) following the unauthorized trading scandal that led to losses of $2.3B at the bank. Swiss financial market regulator Finma said it will watch UBS's investment bank for the foreseeable future and may ask it to raise fresh capital, while the U.K. Financial Services Authority fined UBS $47.6M, the Wall Street Journal reports...Flowers Foods (FLO) could be interested in Twinkies and other products owned by Hostess Brands, and is considered a likely bidder for some of the assets owned by Hostess, the Wall Street Journal reports...REUTERS: The euro zone finance ministers and the IMF will seek to unfreeze the second bailout package for Greece today, but first need to agree if some of the official loans might eventually be forgiven to cut Greek debt, Reuters reports...GlaxoSmithKline (GSK) has no plans to delist its Indian consumer products arm GlaxoSmithKline Consumer Healthcare, said David Redfern, chief strategy officer, Reuters reports...BLOOMBERG: Home equity lines of credit that fueled a spending spree during the U.S.property boom are back. Following six years of declines, lending for so-called Helocs will increase 30% to $79.6B this year, the highest level since the start of the 2008 financial crisis, according to the economics research unit of Moody’s Corp. It projects a 31% jump to $104B next year, Bloomberg reports...Nokia Siemens Networks (NOK, SI) is targeting the U.S. market where Chinese rivals face political hurdles and rising data use entices carriers to spend. The venture is forgoing less lucrative deals in Africa and the Middle East, said CEO Rajeev Suri, Bloomberg reports.
News For UBS;FLO;GSK;NOK;SI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 23, 2015
08:10 EDTGSKArray agrees to acquire rights to encorafenib
Array BioPharma (ARRY) announced that it has reached a definitive agreement with Novartis (NVS) to acquire worldwide rights to encorafenib, a BRAF inhibitor currently in Phase 3 development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline (GSK) on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals. Array previously announced a definitive agreement with Novartis to regain global rights to the Phase 3 MEK inhibitor binimetinib, the material terms of which remain in place following this agreement. In order to address competition concerns raised by the European Commission, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. The European Commission is expected to issue a decision regarding the Novartis-GSK transaction on January 28, 2015. Upon satisfaction of all conditions and closing of the deal, Array will acquire global rights to encorafenib. Other than a de minimis payment due to Novartis from Array, there are no milestone payments or royalties payable under this agreement by either party. Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign or license to Array all patent and other intellectual property rights Novartis owns to the extent relating to encorafenib. As part of the transaction, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. If Array is unable to find a suitable partner in the prescribed time period, a trustee would have the right to sell such European rights. Novartis will conduct and fund the COLUMBUS trial through the earlier of June 30, 2016 or completion of last patient first visit. At that time, Array will assume responsibility for the trial, while Novartis will reimburse Array for out-of-pocket costs along with 50% of Array's full time equivalent costs in connection with completing the COLUMBUS trial. Novartis is responsible for conducting all other encorafenib trials until their completion or transfer to Array for a defined transition period. For all trials transferred to Array, Novartis will reimburse Array for out-of-pocket costs and 50% of Array's FTE costs in connection with completing the trials. Novartis will supply encorafenib for clinical and commercial use for up to 30 months after closing and will also assist Array in the technology and manufacturing transfer of encorafenib. Novartis will also provide Array continued access to several Novartis pipeline compounds for use in currently ongoing combination studies, and possible future studies, including Phase 3 trials, with encorafenib. The effectiveness of the agreement is subject to the receipt of regulatory approvals and to the consummation of the Novartis-GSK transaction. In addition, Array agreed to undertake to obtain certain third party consents or waivers necessary for Array to consummate the transactions under the Novartis Agreement.
07:59 EDTUBSUBS wins dismissal of lawsuit over inactive account seizure, Reuters says
Subscribe for More Information
07:44 EDTGSKGlaxo says now in position to deliver 'tens of thousands' of Ebola vaccine doses
Witty expects to start seeing data from trials of Ebola vaccines in next four to five months. GlaxoSmithKline CEO Andrew Witty speaking on CNBC.
06:39 EDTGSKNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information
January 22, 2015
05:45 EDTNOKNokia reinstated with a Buy at Goldman
January 21, 2015
12:30 EDTGSKGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
January 16, 2015
08:31 EDTGSKGlaxoSmithKline CEO says more IPOs like ViiV could happen, Retuers says
Subscribe for More Information
January 15, 2015
14:31 EDTGSKMylan launches generic Epivir-HBV tablets
Mylan (MYL) announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's (GSK) Epivir-HBV. Mylan received final approval from the U.S. FDA for its Abbreviated New Drug Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1M for the 12 months ending September 30, 2014, according to IMS Health. Currently, Mylan has 284 ANDAs pending FDA approval representing $109.1B in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3B in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
11:23 EDTUBSSEC charges UBS unit with disclosure violations in operating dark pool
The Securities and Exchange Commission has charged a subsidiary of UBS with disclosure failures and other securities law violations related to the operation and marketing of its dark pool. UBS Securities LLC agreed to settle the charges by paying more than $14.4M, including a $12M penalty that is the SEC’s largest against an alternative trading system. An SEC examination and investigation of UBS revealed that the firm failed to properly disclose to all subscribers the existence of an order type that it pitched almost exclusively to market makers and high-frequency trading firms. Furthermore, the SEC investigation found that UBS similarly failed to disclose to all subscribers a “natural-only crossing restriction” developed to ensure that select orders would not execute against orders placed by market makers and high-frequency trading firms. UBS consented to the SEC’s order without admitting or denying the findings. The order censures the firm and requires payment of $2,240,702.50 in disgorgement, $235,686.14 in prejudgment interest, and the $12M penalty.
08:36 EDTGSKOncoMed enrolls first biomarker-selected patient in Notch1 antibody Phase trial
Subscribe for More Information
07:17 EDTUBSUBS volatility at 28 into Swiss ends exchange-rate-cap
Subscribe for More Information
06:42 EDTUBSECB most likely will unveil bond buying program, NY Times says
The European Central Bank is "all but certain" to announce at its next meeting that it will buy government bonds, according to The New York Times. But the ECB may announce that it will buy bonds but say that it will only provide details about the program in March, some believe, the newspaper reported. Some economists contend that the initiative could be a case of "too little, too late," The Times added. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), RBS (RBS) and UBS (UBS). Reference Link
January 14, 2015
06:44 EDTUBSTop court official backs ECB bond buying, NY Times reports
Subscribe for More Information
January 13, 2015
07:19 EDTUBSExtent of UBS restructuring at center of London lawsuit, WSJ reports
Subscribe for More Information
January 12, 2015
12:04 EDTGSKNovartis sees closing GSK transactions in 1H15
Novartis (NVS) says portfolio transformation is progressing "on track." Sees closing GlaxoSmithKline (GSK) transactions in 1H. In 2015, plans to execute integration of GSK oncology business, execute separation of Vaccines, ensure successful start-up of Consumer Health JV with GSK. Sees NBS to continue to deliver synergies. Comments from slides that are being presented at the JP Morgan Healthcare Conference.
09:33 EDTUBSMorgan Stanley hires UBS U.K. investment banker Bishop, FT reports
Nick Bishop, a senior investment banker at UBS (UBS), will leave the company to join Morgan Stanley (MS), where he will become a managing director, sources tell The Financial Times. Reference Link
08:37 EDTGSKShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07:21 EDTUBSEBD Group to hold a conference
Subscribe for More Information
06:22 EDTGSKWHO approves 2 ebola vaccines to enter West Africa trials, Financial Times says
Subscribe for More Information
06:20 EDTUBSUBS loses BAE Systems, Smith & Nephew as broking clients, Financial Times says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use